Trulieve Cannabis (CSE: TRUL) has reported an improvement in its financial results for the second quarter of 2024, showcasing the company’s strategic focus on revenue growth and market expansion. The firm’s net loss narrowed to $12 million, or 4 cents per share, compared to a staggering loss of $404 million, or $1.80 per share, in the same period last year.
On an adjusted basis, Trulieve’s second-quarter net income results were breakeven, outperforming analyst expectations of an 8-cent loss per share, according to FactSet estimates. It is important to note that the wide loss in Q2 2023 included a $307.6 million impairment on goodwill.
Revenue for the quarter surged by 8% year-over-year to $303 million, well ahead of the analyst estimate of $293.7 million. This growth was driven primarily by increased retail traffic and higher wholesale revenue. Trulieve’s gross profit also saw a significant increase, rising to $182 million from $142 million in the previous year. The company’s gross margins expanded to 60%, up from 50%.
READ: Trulieve Cannabis Obtains Two Dispensaries In Ohio Following Litigation Settlement
During the quarter, Trulieve continued to expand its footprint by opening new dispensaries in Florida and Ohio. The company opened dispensaries in Stuart, Brooksville, and North Palm Beach, Florida, and acquired two dispensaries in Beavercreek and Columbus, Ohio. As of the end of the quarter, Trulieve operated 204 stores, with approximately one-third of these located outside of Florida.
“Today marks another milestone, as Trulieve completed our first recreational sale in the state of Ohio with the successful conversion of our three locations to adult use,” CEO Kim Rivers stated. “Second-quarter results demonstrated strength in our core business with our third consecutive quarter of revenue growth and margin expansion. All of the effort and investment over the past two years to set a solid foundation for long-term success is paying dividends.”
Rivers also highlighted Trulieve’s involvement in the Smart & Safe Florida signature campaign, a significant initiative aimed at placing a voter referendum on adult-use cannabis on the November ballot. Trulieve has been a major financial supporter of this $40 million campaign, reflecting its commitment to advancing cannabis legalization efforts and shaping the future of the industry.
Adjusted EBITDA reached $107 million, or 35% of revenue, up 36% year-over-year. The company also generated $71 million in cash flow from operations during the quarter, with free cash flow amounting to $45 million. Trulieve ended the quarter with $356 million in cash reserves, bolstered by a $2 million tax refund received during the period.
Trulieve Cannabis last traded at $12.73 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
